Patrick is the managing editor of PharmaBoardroom
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
Hong Kong Exchanges and Clearing Limited (HKEX) chief executive Nicolas Aguzin has stepped down after a term fraught with upheaval. Having survived COVID-19 isolation, under Aguzin HKEX was confronted with…
As the US Inflation Reduction Act (IRA) starts to become a reality, and both big pharma and biotech companies brace themselves for its more widespread impact, BIO names Washington fixture,…
In the latest blow to Indian pharma’s reputation, the European Medicines Agency (EMA) has recommended the suspension of marketing authorisations for a large number of generics tested by Indian CRO…
A roundup of the biggest stories from UK pharma, including the latest agreement between the British government and industry on a renewed drug pricing clawback scheme; GSK’s search for deals…
The APAC region —with an approximate ten percent growth in trial numbers between 2017 and 2022— is rapidly becoming the world’s leading market for clinical trials. Karen Chu, CEO of…
The European Union’s just-released and first essential medicines list is the latest in a series of measures designed to limit the bloc’s reliance on countries outside its borders and avoid…
A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’…
AstraZeneca has made a bold move by offering its in-house digital clinical trial expertise to clinical research organisations (CROs) and other pharmaceutical companies via the launch of healthtech business Evinova.…
Eli Lilly has turned its numbers around and become the world’s most valuable pharma company, thanks to its type 2 diabetes and off-label use obesity drug tirzeptide, which generated no…
The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
See our Cookie Privacy Policy Here
